• Return to Headlines

Shares of Supernus Pharmac Has Risen Above Previous 52-Week High

By James Quinn

Supernus Pharmac (NYSE:SUPN) traded at a new 52-week high today of $46.99. Approximately 115,000 shares have changed hands today, as compared to an average 30-day volume of 595,000 shares.

Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company. The Company develops and markets proprietary drugs for the treatment of central nervous system diseases and disorders. Supernus has developed a portfolio of clinical stage drugs to address neurological and psychological problems such as epilepsy, conduct disorder, Parkinson's disease, ADHD, depression and anxiety.

Supernus Pharmac (NYSE:SUPN) is currently priced 4.9% above its average consensus analyst price target of $44.17. The stock should discover initial support at its 200-day moving average (MA) of $15.68 and subsequent support at its 50-day MA of $15.55.

In the past 52 weeks, shares of Supernus Pharmac have traded between a low of $17.25 and a high of $46.99 and are now at $46.45, which is 169% above that low price. Over the past week, the 200-day moving average (MA) has gone down 0.5% while the 50-day MA has advanced 1.4%.

SmarTrend is tracking the current trend status for Supernus Pharmac and will alert subscribers who have SUPN in their portfolio or watchlist when shares have changed trend direction.

Keywords: 52 week high/lows supernus pharmac

Ticker(s): SUPN